Drugs / DEA-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05375253 | Apr 2023 | leukemia | University of Nebraska | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEA-NK | “αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY” NCT05375253 ↗ |
| Modality | Cell therapy | “haploidentical cytokine activated natural killer (NK) cell immunotherapy” NCT05375253 ↗ |
| Route | Other | “Infusion of DEA-NK on day +7 post-transplant” NCT05375253 ↗ |